TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02334683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
Study: NCT04260763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Group
Description: Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Mobile App
Description: The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking.
Study: NCT00502723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy
Description: Radical retropubic prostatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical laparoscopy prostatectomy
Description: Radical laparoscopy prostatectomy
Study: NCT02340013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
Study: NCT02631655

Intervention type: OTHER
Group type: OTHER
Intervention: impact of device 18F-FDOPA PET on treatment decisions
Description: Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
Study: NCT03537326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
Study: NCT04101357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT411
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT411
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT411
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: intravenous
Study: NCT04333784

Intervention type: OTHER
Intervention: Exercise training
Description: Exercise with blood flow restriction (with a pneumatic cuff).
Study: NCT03858855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Diary
Description: Complete journal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject Diary
Description: Complete journal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subject Diary
Description: Complete journal
Study: NCT01778933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17
Study: NCT04667767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WASH kit
Description: WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: National standard outpatient treatment for uncomplicated severe acute malnutrition
Study: NCT02269020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Dissection
Description: Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
Study: NCT03852641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of feeding
Description: Feeds will be given via nasogastric tube over 15-30 min versus 2 hr

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Length of feeding
Description: Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
Study: NCT01988857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
Study: NCT04097808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
Study: NCT01972503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and oxaliplatin
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
Description: Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
Study: NCT04379882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Sedation (Silva)
Description: Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
Study: NCT02392741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
Study: NCT01057654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: Pravastatin 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifibrol
Description: Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
Study: NCT00775645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetyl-L-carnitine hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02289079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Study: NCT01941641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant FOLFOXIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT00680043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
Study: NCT03715166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide Oral Solution
Description: Oral Solution dosed at 0.5mg/mL Taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution Taken twice daily
Study: NCT01196923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopically Guided Ablation
Description: Visually Guided Ablation using EAS-AC
Study: NCT04532957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: QD oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: QD oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: QD oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules
Study: NCT03773705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery versus scalpel
Description: Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery versus scalpel
Description: Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
Study: NCT03181204

Intervention type: PROCEDURE
Intervention: Bronchial biopsy
Description: The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Intervention type: PROCEDURE
Intervention: Bronchial biopsy
Description: The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
Study: NCT05160454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: near infrared spectroscopy
Description: evaluate cerebral blood flow with and without breatholding

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: near infrared spectroscopy
Description: evaluate cerebral blood flow with and without breatholding
Study: NCT00696176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT 3 DECOY
Description: single administration to a head and neck tumor
Study: NCT02447549

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBRT
Description: One RT plan with whole bladder treated to standard dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SART
Description: Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DART
Description: Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
Study: NCT02887521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: pulmonary rehabilitation participant manual

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: pulmonary rehabilitation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometer
Description: receive a pedometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: receive a pamphlet with exercises plus the standard course of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: patients undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: patients undergo surgery
Study: NCT03128333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RunKeeper app + physiotherapy coaching
Description: RunKeeper app for half a year to self-monitor leisure-time PA.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
Study: NCT04177342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
Study: NCT02966587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03668314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929
Description: Single dose from 2 mg to TBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929 TBD dose
Description: Fed vs fast dose TBD based upon results of previous cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDN-929
Description: Multiple dose based on results of previous cohorts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo multiple dose
Study: NCT04620720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capule gabapentin
Description: neuropathic analgesic
Study: NCT01569711

Intervention type: PROCEDURE
Intervention: Deep brain stimulation of nucleus accumbens
Description: * Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)
Study: NCT02530554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Single application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Single application
Study: NCT02355353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: imaging arm
Description: DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
Study: NCT03487757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
Study: NCT00005972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT00692393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann intervention
Description: sigmoid resection, peritoneal and rectal lavage, terminal stoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protected anastomosis resection
Description: sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
Study: NCT00005972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02138760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI UroNav fusion biopsy
Study: NCT01752907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General Education DVD
Description: A general chemotherapy side effects education DVD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Pain Education DVD
Study: NCT02543645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Varlilumab and Atezolizumab
Description: Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg.